6533b834fe1ef96bd129d9e4
RESEARCH PRODUCT
High frequency of subclonal ALK mutations in high risk neuroblastoma patients. A SIOPEN study
Angela BelliniVirginie BernardEve LapoubleNathalie ClementGaelle PierronInge M. AmbrosKatleen De PreterNadine Van RoyAles VichaValérie CombaretDavid BettsMarta JeisonSmadar AvigadMartina MoriniLuigi VaresioBarbara Marques9Annick MuhlethalerRosa NogueraAna BerbegallJaime Font De MoraPeter F. AmbrosRuth LadensteinDominique Valteau-couanetJean MichonOlivier DelattreNick BownDeborah TweddleGudrun Schleiermachesubject
NeuroblastomaALKhemic and lymphatic diseasesHigh RiskSIOPENDoenças Genéticasdescription
Introduction: In neuroblastoma (NB), activating ALK receptor tyrosine kinase point mutations are detected in 8–10% at diagnosis using conventional sequencing. To determine the potential occurrence and the prognostic impact of ALK mutations in a series of high risk NB patients we studied ALK variation frequencies using targeted deep sequencing in samples of patients enrolled in the SIOPEN HR-NBL01 study
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2015-11-01 |